Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mezlocillin is a broad-spectrum semisynthetic penicillin antibiotic of the ureidopenicillin subclass. It is derived from ampicillin and was developed by Bayer. Mezlocillin acts by binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the final stage of peptidoglycan synthesis and leading to cell lysis. It is active against a wide range of Gram-negative bacteria (including *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella* species) as well as some Gram-positive organisms. Unlike most extended-spectrum penicillins, it is primarily excreted via the liver and thus useful for biliary tract infections such as ascending cholangitis. Mezlocillin was administered intravenously or intramuscularly due to poor oral absorption and has been discontinued in the United States[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mezlocillin.